Rajiv Gandhi Cancer Institute and Research Centre | Clinical Research (Dr D.C.Doval)

Research site

(Unclaimed)

Location

D-18, Sector 5, Rohini, New Delhi, Delhi, India

Site insights

Top conditions

Top treatments

Dacomitinib

Palbociclib

Lorlatinib

Durvalumab

Ravulizumab

LY3537982

Enzalutamide

Pembrolizumab

PF-07220060

Letrozole

Parent organization

This site is a part of Rajiv Gandhi Cancer Institute and Research Centre

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 24 total trials

Locations recently updated

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting

Neoplasms

Drug: Cetuximab

Drug: Oxaliplatin

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: Pemetrexed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Crizotinib

Drug: Repotrectinib

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Selpercatinib

Locations recently updated

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment (ACCESS-1)

This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on patie...

Enrolling

Paroxysmal Nocturnal Hemoglobinuria

Drug: Pozelimab

Drug: Ravulizumab

Locations recently updated

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Mezigdomide

Drug: Dexamethasone

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Enrolling

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Researchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive.* Metastatic means can...

Active, not recruiting

Non-Small-Cell Lung Carcinoma

Lung Neoplasms

Biological: Pembrolizumab/Vibostolimab

Biological: Pembrolizumab

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition...

Enrolling

Biliary Tract Cancer

HER2 Gene Mutation

Drug: Cisplatin

Drug: Gemcitabine

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan...

Active, not recruiting

Neuroblastoma

Rhabdomyosarcoma

Drug: Cyclophosphamide

Drug: Temozolomide

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting

Prostate Cancer

Drug: Placebo plus enzalutamide

Drug: talazoparib plus enzalutamide